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ABSTRACT
We evaluated 10/10 HLA antigen–matched unrelated hematopoietic cell transplantation (HCT) after nonmy-
eloablative conditioning with fludarabine 3  30 mg/m2 and 2 Gy of total body irradiation as treatment for
patients with chronic myeloid leukemia who were ineligible for conventional HCT. Data from 21 consecutive
patients in first chronic phase (CP1; n  12), accelerated phase (AP; n  5), second CP (CP2; n  3), and blast
crisis (n  1) were analyzed. Stem cell sources were bone marrow (n  4) or granulocyte colony-stimulating
factor–mobilized peripheral blood mononuclear cells (G-PBMCs; n  17). The patient who underwent
transplantation in blast crisis died on day 21 (too early to be evaluated for engraftment) from progressive
disease. Sustained engraftment was achieved in 5 of 12 patients who underwent transplantation in CP1, 4 of 5
patients who underwent transplantation in AP, and 2 of 3 patients who underwent transplantation in CP2,
whereas 9 patients rejected their grafts between 28 and 400 days after HCT. Specifically, 1 of 4 marrow
recipients and 10 of 17 G-PBMC recipients achieved sustained engraftment. Graft rejections were nonfatal in
all cases and were followed by autologous reconstitution with persistence or recurrence of chronic myeloid
leukemia. Seven of 11 patients with sustained engraftment—including all 5 patients in CP1, 2 of 4 patients in
AP, and neither of the 2 patients in CP2—were alive in complete cytogenetic remissions 118 to 1205 days
(median, 867 days) after HCT. Two of the remaining 4 patients died of nonrelapse causes in complete (n  1)
or major (n  1) cytogenetic remissions, and 2 died of progressive disease. Further efforts are directed at
reducing the risk of graft rejection by exclusive use of G-PBMC and increasing the degree of pretransplan-
tation immunosuppression.
© 2005 American Society for Blood and Marrow Transplantation
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uNTRODUCTION
Despite promising results with imatinib mesylate [1],
llogeneic hematopoietic cell transplantation (HCT) has
emained the only proven curative therapy for chronic
yeloid leukemia (CML) [2,3]. Cures have been attrib-m. B. and M. B. M. contributed equally to this work.
72ted to both the myeloablative conditioning regimens
nd the graft-versus-tumor effects [4,5] mediated by do-
or immune cells. Myeloablative conditioning regimens
or HCT have evolved remarkably during the last de-
ade. Adjustment of busulfan plasma concentrations on
he basis of pharmacokinetic studies has avoided both (1)
ndertreatment and the risk of relapse and (2) overtreat-
ent and the risk of excessive toxicity [6,7]. With tar-
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Nonmyeloablative Unrelated HCT for CML
Beted busulfan and cyclophosphamide conditioning, sur-
ival rates of 86% at 3 years have been achieved in
elatively young (median age, 43 years) and otherwise
ealthy patients with CML in ﬁrst chronic phase (CP1)
iven HLA-matched related HCT [8].
Additionally, considerable experience has been
btained with unrelated HCT. Five-year overall sur-
ival has been 74% for CP1 patients younger than 50
ears who received HCT within 1 year of diagnosis
9]. However, 2-year survival has been 40% in pa-
ients 50 to 55 years of age [9], and transplantations
ave generally not been performed in patients older
han 55 years [10,11]. This is unfortunate, because the
edian patient age at diagnosis for CML is 67 years.
Graft-versus-tumor effects have been well docu-
ented for CML, as evidenced by the ability of donor
ymphocyte infusions (DLIs) to induce durable complete
emissions in patients who relapse after allogeneic HCT
12,13]. To extend the use of allogeneic HCT to include
lder patients with CML and those with comorbid con-
itions, several groups of investigators have introduced
educed-intensity [14-17] or truly nonmyeloablative [18-
2] conditioning regimens. Those regimens have fewer
oxicities than ablative ones but are sufﬁciently immu-
osuppressive for allogeneic engraftment and rely on
raft-versus-tumor effects for tumor eradication [23].
n the basis of initial experimental canine studies [24]
nd subsequent studies in HLA-identical sibling recipi-
nts [18], we have developed a nonmyeloablative regi-
en that uses 2 Gy of total body irradiation (TBI) and
udarabine 3 30 mg/m2 as conditioning for unrelated
LA-matched HCT [25,26]. Postgrafting immunosup-
ression with mycophenolate mofetil (MMF) and cyclo-
porine (CSP) is aimed at both enhancing engraftment
nd controlling graft-versus-host disease (GVHD).
hree phase I/II studies have explored variations in the
uration and dosing of postgrafting immunosuppression
or unrelated HLA-matched HCT in patients with var-
ous hematologic malignancies [25,26]. Here, we retro-
pectively analyzed outcomes among 21 consecutive pa-
ients with CML who were included in those studies.
ATIENTS AND METHODS
atients
Data from 21 consecutive patients with CML in
P1 (n  12), CP2 after blast crisis (BC) (n  3),
ccelerated phase (AP; n  5), or BC2 (n  1) and who
nderwent transplantation between January 2000 and
arch 2004 under Fred Hutchinson Cancer Research
enter (FHCRC) multi-institutional protocols 1463
n  14), 1641 (n  5), and 1668 (n  2) were analyzed
s of June 31, 2004 (Table 1). The median patient age
as 54 years (range, 33-66 years). The median time from
iagnosis to HCT was 26 months (range, 5-121
onths). Two patients had experienced treatment fail- i
B & M Tre with myeloablative allogeneic HCT as the result of
ither disease progression or graft rejection. Six patients
ad experienced treatment failure with imatinib therapy
ecause of intolerance (n  3) or lack of cytogenetic
esponses to the drug given at 800 mg/d (n  3). Four
atients (all included in protocol 1463) received marrow
nd 17 received granulocyte colony-stimulating factor–
obilized peripheral blood mononuclear cells (G-PBMCs)
s stem cell sources. Two patients each had single HLA
lass I allele mismatches with their donors, whereas the
emaining 19 patients were matched for 10/10 HLA
ntigens/alleles. Participating institutions included the
HCRC, the University of Washington Medical Cen-
er, the Veterans Affairs Medical Center (all in Seattle,
A; n 12), Stanford University (Palo Alto, CA; n 4),
he University of Colorado (Denver, CO; n  2), the
niversity of Utah (Salt Lake City, UT; n  2), and
aylor University (Dallas, TX; n  1). Patients were
onsidered ineligible for conventional allogeneic
CT because of age (older than 50 years; n  17),
edical comorbidities (n  2), or failed preceding
yeloablative allogeneic HCT (n  2). The study
rotocols were approved by the institutional review
oards at FHCRC and each of the collaborating sites.
ll patients signed consent forms approved by the
ocal institutional review boards.
onditioning Regimen, Postgrafting
mmunosuppression, and Follow-up
Patients were conditioned with ﬂudarabine 30 mg/
2/d on days 4, 3, and 2 and with 2 Gy of TBI
n the day of HCT [26]. Postgrafting immunosup-
ression included MMF and CSP in all 3 protocols.
rotocol 1463 administered MMF 15 mg/kg orally
wice a day from the evening of day 0 until day 40,
ith taper through day 96. CSP was administered at
.25 mg/kg orally twice a day, from day 3 to day
100, with taper through day 180 [26]. Protocol 1641
ncluded MMF 15 mg/kg orally thrice a day from the
vening of day 0 until day 40, with taper through
ay 96, and CSP was given identically to protocol
463. In protocol 1668, MMF was given at 15 mg/kg
rally thrice a day from the evening of day 0 until day
30 and at 15 mg/kg orally twice a day from day 31
ntil day 150, with a subsequent taper through day
80, whereas CSP was given at 6.25 mg/kg orally
wice a day from day 3 to day 80.
Diagnosis, clinical grading, and treatment of
VHD were performed as previously reported
26,27]. Standard prophylaxis against Pneumocystis
arinii, fungal infections, toxoplasmosis, and cytomeg-
lovirus infections was used [26].
Pathology, cytogenetics, and reverse transcriptase–
olymerase chain reaction (RT-PCR) monitoring
ere performed on days 28, 56, 84, and 180 and yearly
hereafter. In patients who underwent transplantation
n Seattle, quantitative RT-PCR was performed by
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Table 1. Patients and Results of HCT
Patient
No.
Disease
Stage
Time
between
Diagnosis
and HCT
(mo)
Patient
Age
(y)/Sex Comorbidities at HCT
Stem Cell
Source
CD34
Cell
Doses
(106/kg)
CD3 Cell
Doses
(108/kg)
% Day 28
Donor T-Cell
Chimerism
Rejection
(Day)
Acute
GVHD
(Grade)
Extensive
Chronic
GVHD
Survival, days
(Disease Status)
1 BC2 52 33/M Prior HCT with URD; VOD; CRF Marrow 1.88 0.29 ND NE 0 NE 21 (PD)*
2 CP2 65 61/M G-PBMC 3.28 3.62 70 No III Yes 233 (PD)*
3 CP2 121 63/F G-PBMC 4.13 2.04 62 No III No 164 (MCR)*
4 CP2 88 60/F G-PBMC 6.28 1.18 15 Yes (42) II No 540 (PD)*
5 AP 5 36/F Two prior HCT with MRD Marrow 2.76 0.46 ND No II Yes 241 (PD)*
6 AP 54 66/M G-PBMC 5.5 2.2 45 No I Yes 267 (CCR)†
7 AP 92 63/F G-PBMC 5.5 2.1 90 No 0 Yes 478 (CCR)*
8 AP 29 58/M G-PBMC 5.28 1.8 99 No II No 115 (CCR)†
9 AP 12 53/F G-PBMC 3.5 3.69 10 Yes (266) 0 No 271 (PD)*
10 CP1 13 52/F G-PBMC 7.26 1.7 41 No II Yes 1205 (CCR)†
11 CP1 9 54/F G-PBMC 4.03 3.27 80 No II Yes 1126 (CCR)†
12 CP1 9 52/M G-PBMC 1.18 2.13 66 No II Yes 1123 (CCR)†
13 CP1 11 61/M G-PBMC 2.9 2.27 90 No II Yes 867 (CCR)†‡
14 CP1 24 54/M G-PBMC 9.58 2.84 28 No§ III NE 118 (CCR)†
15 CP1 26 54/M Marrow 2.37 0.26 7 Yes (43) 0 No 1188 (CML)†
16 CP1 — 54/F G-PBMC 5.51 ND 50 Yes (79) 0 No 960 (CML)†
17 CP1 11 38/M Obesity, AVM G-PBMC 6.44 1.61 40 Yes (400) II Yes 946 (CML)†
18 CP1 24 58/M G-PBMC 2.29 ND 0 Yes (28) 0 No 806 (PD)*
19 CP1 29 53/M Marrow 1.3 ND 0 Yes (29) 0 No 698 (CML)†
20 CP1 26 51/M G-PBMC 3.3 0.9 10 Yes (54) 0 No 734 (CML)†
21 CP1 36 40/F Obesity G-PBMC 10.7 5.39 19.5 Yes (211) II No 356 (CML)†
BC2 indicates second blast crisis; CP2, second chronic phase; AP, accelerated phase; CP1, ﬁrst chronic phase; M, male; F, female; HCT, hematopoietic cell transplantation; URD, unrelated donor; VOD,
veno-occlusive disease of the liver; CRF, chronic renal failure; MRD, HLA-matched related donor; AVM, arteriovenous malformation; G-PBMC, granulocyte colony-stimulating factor–mobilized
peripheral blood mononuclear cells; ND, not done; NE, not evaluable; PD, progressive disease; CCR, complete cytogenetic response; MCR, major cytogenetic response; CML, chronic myeloid
leukemia.
*Dead.
†Alive.
‡Had PD after HCT but achieved CCR after 1 course of farnesyl transferase inhibitor and extensive chronic GVHD.
§The patient had 28% donor T-cell chimerism on day 28; this predicted a high risk of subsequent graft rejection. He received pentostatin (4 mg/m2) on day 43 followed by donor lymphocyte infusion
2 days later. This resulted in a signiﬁcant increase in donor chimerism among all subpopulations, and the patient is currently surviving with sustained graft 118 days after HCT.
F.Baron
et
al.
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Nonmyeloablative Unrelated HCT for CML
Bsing 5= exonuclease–based ﬂuorogenic real-time RT-
CR to detect bcr/abl and 2-microglobulin messen-
er RNA. Assays were performed in single tubes in an
BI PRISM 7700 sequence detector (PE Applied Bio-
ystems, Foster City, CA), as previously described
28].
Persistent, progressive, and relapsed CML in the
bsence of severe manifestations of acute and chronic
VHD was treated by rapid discontinuation of systemic
mmunosuppression to initiate graft-versus-tumor ef-
ects. Percentages of donor-host chimerism levels in
arrow, T cells, and granulocytes were determined by
sing ﬂuorescent in situ hybridization for X- and Y-
hromosomes if patients and donors were sex mis-
atched or by PCR-based ampliﬁcation of variable
umber tandem repeat sequences unique to donors and
osts if patients and donors were sex matched [26,29].
tatistical Methods
Survival was estimated by the Kaplan-Meier method.
rogression was deﬁned as increases in pretransplanta-
ion numbers of metaphases with the Philadelphia
hromosome by 25% after discontinuation of im-
unosuppression, the development of new clonal cy-
ogenetic abnormalities, or evidence of transformation
o AP or BC. Complete cytogenetic remission was
eﬁned as the disappearance of Philadelphia chromo-
ome and any other clonal abnormalities, and major
ytogenetic response was deﬁned as a decrease of
hiladelphia chromosome–positive marrow metaphases
o 25%. Cumulative incidence estimates were calcu-
ated for GVHD and nonrelapse mortality. Deaths
ere treated as competing events in analyses of
VHD. All P values were derived from likelihood
atio statistics and were 2 sided.
ESULTS
eripheral Blood Cell Changes, Donor
ngraftment, and Graft Rejection
Patients experienced declines in both neutrophil
nd platelet counts after conditioning. Neutrophil and
latelet nadirs were 0.1  109/L (range, 0.0-0.9 
09/L) and 43  109/L (range, 6-373  109/L), re-
pectively. Median numbers of red blood cell and
latelet transfusions were 8 (range, 0-32) and 0 (range,
-10), respectively. Median durations of neutropenia
deﬁned as absolute neutrophil count 0.5  109/L)
nd thrombocytopenia (deﬁned as platelet count20
09/L) were 7 days (range, 0-20 days) and 0 days
range, 0-17 days), respectively. One patient died on
ay 21 (too early to be evaluated for engraftment)
rom BC (Table 1). Initial donor engraftment (deﬁned
s 5% donor T-cell chimerism) was observed in 18
90%) of the 20 remaining patients and was sustained
n 1 of 4 marrow and 10 of 17 G-PBMC recipients, d
B & M Thereas 9 patients did not engraft or rejected initial
rafts 28 to 400 days after HCT. All graft rejections
ere nonfatal and were followed by autologous hema-
opoietic reconstitution and persistence or recurrence
f CML.
ay 28 T-Cell Chimerism Levels <40% Predicted
ubsequent Graft Rejection
Day 28 T-cell chimerism was assessed in 19 pa-
ients (Table 1). Eight of 9 patients with donor T-cell
himerism levels 40% on day 28, compared with 1
f 10 with levels 40%, subsequently rejected their
rafts (P  .001). Patient 14, who had a day 28 donor
-cell chimerism level of 28%, received pentostatin
4 mg/m2) on day 43, followed by DLI on day 45, in
successful attempt to prevent graft rejection. Donor
himerism levels among T cells, granulocytes, and
arrow mononuclear cells increased after pentostatin
dministration and DLI (Figure 1A), and the patient
xperienced sustained engraftment.
utcomes in Patients with Graft Failure or Graft
ejection (n  9)
Among the 9 patients with graft rejection, 4 in
P1 achieved unsustained complete cytogenetic re-
issions 56 to 107 days after HCT, whereas 3 in CP1,
in AP, and 1 in CP2 had persistence of CML. The
patients with cytogenetic remissions eventually ex-
erienced disease progression that began in 1 case 198
ays before graft rejection was diagnosed and that
egan in the other 3 cases 112, 113, and 230 days after
raft rejection. At the time of the analyses, 3 patients
ad died of progressive disease, and 6 were alive with
ML.
utcomes in Patients with Sustained Engraftment
n  11)
Sustained engraftment was demonstrated in 5 of
2 patients with CP1, 4 of 5 patients with AP, and 2 of
patients with CP2. Grade II and III acute GVHD
ccurred in 6 (55%) and 3 (27%) patients with sus-
ained engraftment, respectively; no grade IV acute
VHD was observed. Extensive chronic GVHD was
een in 8 patients.
Seven of 11 patients with sustained engraftment,
ncluding 4 of 5 in CP1, 3 of 4 in AP, and none of 2
n CP2, achieved sustained complete cytogenetic re-
issions, whereas 1 patient who underwent transplan-
ation in CP2 achieved a major cytogenetic remission
Table 1). The ﬁfth patient with CP1 developed BC
89 days after HCT but then achieved a complete
ytogenetic remission and became BCR/ABL negative
y quantitative RT-PCR after a short course of ther-
py with a farnesyl transferase inhibitor (3 days of
onafarib [SCH66336, Sarasar] given at 200 mg twice
aily) and experienced development of chronic exten-
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2ive GVHD. One patient with CP2 and 1 with AP
ied of progressive disease, and 1 patient each in CP2
nd AP died of nonrelapse causes; 1 of the 2 had a
ajor cytogenetic response, and the other was in com-
lete cytogenetic remission. Figure 1B shows the evo-
ution of BCR/ABL messenger RNA testing in 5 pa-
ients with sustained engraftment who underwent
ransplantation for CML in CP1 (n  4) or AP (n 
). All 5 patients achieved molecular negativity 84 to
24 days (median, 230 days) after HCT.
The 100-day and 1-year nonrelapse mortalities for
atients with sustained engraftment were 0% and 11%,
espectively. The 1-year probabilities of overall survival
ere 100%, 67%, and 0% for patients with sustained
ngraftment who underwent transplantation in CP1,
P, and CP2, respectively (Figure 2). Figure 3 shows
verall and progression-free survivals in all patients (re-
igure 1. A, Peripheral blood donor T cell, granulocyte, and
arrow mononuclear cell chimerism levels in patient 14, with CML
n CP1. The patient had 28% donor T-cell chimerism on day 28,
nd this predicted a high risk of subsequent graft rejection. He
eceived pentostatin (4 mg/m2) on day 43, followed by donor lym-
hocyte infusion 2 days later. This resulted in a signiﬁcant increase
n donor chimerism among all subpopulations, and the patient is
urrently surviving with a sustained graft 118 days after HCT. B,
volution of BCR/ABL messenger RNA in 4 patients with CML in
P1 and 1 patient with CML in AP who had sustained engraftment.
olecular remissions were achieved 84 to 524 days (median, 230
ays) after HCT. Values of 0.1 indicate negative quantitative RT-
CR.ectors and nonrejectors) included in this study. a
76ISCUSSION
The patients with CML reported here took part in
phase II protocols that explored engraftment, toxic-
ties, and efﬁcacy of a nonmyeloablative conditioning
egimen for unrelated HCT in patients with various
ematologic malignancies. Although the conditioning
egimen of ﬂudarabine and 2 Gy of TBI remained the
ame, the protocols differed slightly from each other
ith regard to stem cell sources (marrow versus G-
BMC) and the duration and dosing of postgrafting
MF and CSP.
A main ﬁnding among patients with CML has been
ailure of sustained engraftment, which was observed in
igure 2. Overall survival in patients with CML in CP1, AP, and
P2 who had sustained engraftment.
igure 3. Overall survival (A) and progression-free survival (B) in
ll patients (n  21).
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Nonmyeloablative Unrelated HCT for CML
Bof 20 evaluable cases. This observation contrasted with
bservations in CML patients given related grafts after
onditioning with 2 Gy of TBI and ﬂudarabine, all 10 of
hom achieved sustained engraftment [30], and also
ith ﬁndings in 64 other patients given unrelated grafts
or acute myeloid leukemia, 61 of whom (95%) achieved
ustained engraftment [31]. In each case, graft failure was
ollowed by autologous marrow recovery with a return
o the status quo. This is different from conventional
CT, for which graft failures have been seen in 5% to
5% of CML patients, and subsequent marrow aplasia
as the rule [9,10]. A high rate of graft rejection among
ML patients receiving grafts from unrelated donors
fter reduced-intensity conditioning has also been re-
orted by other investigators. A graft failure rate of 44%
3 of 8 patients) was described after a reduced-intensity
onditioning regimen that combined ﬂudarabine, busul-
an, and antithymocyte globulin [32], and, recently, Hal-
emeier [33] observed graft failure in 5 of 22 evaluable
atients given unrelated G-PBMC as treatment of CML
fter conditioning with 5.5 Gy of TBI and cyclophosph-
mide. A previous analysis of data from the ﬁrst 89
atients with various hematologic malignancies given
nrelated grafts after conditioning with ﬂudarabine and
Gy of TBI showed that marrow grafts were associated
ith a higher incidence of graft failure than G-PBMC
rafts [26]. Recent analyses of data in 130 consecutive
atients given unrelated grafts after nonmyeloablative
onditioning showed that a higher number of grafted
D8 (P .005) and CD34 (P .01) cells resulted in
lower probability of graft rejection [34]. Two of the 4
urrent marrow recipients experienced graft failure, 1 of
he 4 died too early for evaluation, and the only patient
ith engraftment had experienced treatment failure with
previous high-dose conventional allogeneic HCTs.
evertheless, 7 of the 17 G-PBMC recipients also re-
ected their grafts. Increasing the dosing of postgrafting
MF from 15 mg/kg every 12 hours to 15 mg/kg every
hours reduced the rejection rate in G-PBMC recipi-
nts from 5 in 10 to 2 in 7, but not convincingly so.
learly, more effective pretransplantation immunosup-
ression will be required to ensure uniform engraftment.
dose relationship with respect to TBI and allogeneic
arrow engraftment has been demonstrated [35,36] in a
reclinical canine model. This led us to conduct a dose-
scalation study to determine the minimal dose of TBI
equired to promote engraftment in 90% of CML
atients given grafts from unrelated donors.
Eight of 9 current patients with day 28 donor
-cell chimerism levels 40% rejected their grafts,
hus conﬁrming previous observations in patients with
ther hematologic malignancies [37]. These ﬁndings
ed to the design of a protocol aimed at preventing
raft rejection through administration of pentostatin
to reduce host-versus-graft reactions) followed by
LI, as was used in 1 of the current patients, who had
day 28 donor T-cell chimerism level of 28%. Al- C
B & M Though the strategy was apparently successful in this
atient, more experience will be needed to conﬁrm its
fﬁcacy [38].
Sustained complete cytogenetic remissions have
een achieved in all but 1 of the patients with CML in
P1 or AP who had stable engraftment. The relatively
ong time periods required for remissions to be com-
lete were consistent with the concept that remissions
ere due to graft-versus-tumor effects. Nonrelapse
ortality in patients with sustained engraftment was
% at 100 days and was 11% at 1 year after HCT.
his was encouraging given the age of the patients,
he median time interval (2 years; range, 0.5-10
ears) between diagnosis and HCT, and the advanced
isease stage in 9 of the patients. The 1-year proba-
ilities of overall survival in patients with CP1, AP,
nd CP2 who had sustained engraftment were 100%,
6%, and 0%, respectively. These observations at-
ested to the relative safety of the current regimen and
uggested that HCT should be considered early in the
isease course, preferentially when patients were still
n CP1. Ideal candidates for this approach would be
atients who either are intolerant of imatinib mesylate
r do not achieve 3-log BCR/ABL reductions after 1
ear of treatment with the drug [1].
In summary, unrelated donor HCT after nonmy-
loablative conditioning with ﬂudarabine and low-
ose TBI was feasible with relatively low nonrelapse
ortality. Sustained complete cytogenetic remissions
ere achieved in most patients who had stable en-
raftment, but graft rejection occurred in 45% of
atients. Further efforts are directed at reducing the
isk of rejection by exclusive use of G-PBMC and by
ncreasing the degree of pretransplantation immuno-
uppression.
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